Key Points

Indian pharma exporters await clarity as US tariffs on imports take effect next week. Pharmexcil's VP outlines potential strategies companies may adopt, from price hikes to inventory adjustments. Meanwhile, Congress leader Jairam Ramesh condemns Trump's unilateral trade moves as destructive to global institutions. The commerce ministry is consulting industry stakeholders to assess the tariff's full impact.

Key Points: Pharmexcil VP Mehta on US 25% Tariff Impact for Indian Pharma Firms

  • Pharmexcil VP lists 3 strategies for Indian pharma firms to tackle US tariffs
  • Trump's 25% duty delayed to August 7 for 69 nations
  • Congress' Jairam Ramesh slams Trump for undermining WTO rules
  • Commerce Minister Goyal holds stakeholder talks on tariff fallout
3 min read

We are still waiting for final outcome...: Pharmexcil Vice Chairman on US's 25% tariff on Indian products

Pharmexcil VP Bhavin Mehta outlines scenarios for Indian pharma firms as US tariffs loom, while Congress criticizes Trump's trade policies.

"We are still waiting for the final outcome... then we can see how tariffs will be implemented – Bhavin Mukund Mehta"

New Delhi, August 1

With US President Donald Trump's decision to impose 25 per cent tariffs on goods imported from India set to take effect soon, Pharmaceuticals Export Promotion Council of India Vice Chairman Bhavin Mukund Mehta has laid out multiple scenarios for the Indian pharmaceutical companies operating in the US under the new tariff regime.

"I think we are still waiting for the final outcome, which is going to come tomorrow. Then we can see exactly how the tariffs are going to be implemented and on which products, " Mehta told ANI.

Trump had announced that India's tariff rate would be effective August 1, but an executive order signed for 69 countries - with India on the list - says the new tariff rates will be applicable from August 7.

"In the first case, it might happen that we are able to charge the 25 per cent to customers, ultimately the cost of the medicine will go up. The second scenario is that companies exporting there have a product mix. What can happen is whichever is the expensive product and whichever is the low-cost product, they might balance between the two. They might pass on some tariffs, and they might absorb others," Mehta said.

"The third thing is all the big companies that are there, they might have warehouses over there, they might be able to transfer goods over there, and they pay the tariffs. The point is that there are possibilities."

The US's move has raised concerns about India's export outlook, as the US is one of the country's largest export destinations. The fresh round of tariffs has sparked fears that Indian products will become more expensive in the US market, making them less competitive compared to goods from other countries, potentially denting demand.

Meanwhile, Congress General Secretary Jairam Ramesh on Friday said India cannot be a "mute spectator" when US President Donald Trump's repeated tariff threats on countries, including India, "destroys" the multilateral trading system established by the World Trade Organisation.

Noting India's stake in international accords and institutions, Jairam Ramesh emphasised that Trump has already "gutted" the World Health Organisation and withdrawn from the Paris Climate Agreement and UNESCO.

"The WTO had been dealt very heavy blows during Trump I. It has been destroyed during Trump II. The rules-based, multilateral trading system put in place with the US itself playing a leadership role has been finished off. The US's approach now is to negotiate--if at all--bilaterally but finally decide unilaterally. President Trump has also gutted the WHO and withdrawn from the Paris Climate Agreement and UNESCO. India has the highest stakes in such international accords and institutions," Congress MP wrote in a social media post on X.

Union Commerce and Industry Minister Piyush Goyal said the Ministry of Commerce and Industry is holding talks with exporters, industries and all stakeholders and gathering information on their assessment of this issue.

- ANI

Share this article:

Reader Comments

S
Sarah B
As someone working in pharma exports, I can say companies have been preparing for this. Many have already started diversifying to other markets like Africa and Latin America. Smart move!
A
Arjun K
Why is our government always reactive instead of proactive? We knew Trump's policies from his first term. Should have had contingency plans ready by now. This last-minute scrambling looks bad.
P
Priya S
The US needs our medicines more than we need their market. Let them pay higher prices if they want quality generics. Indian pharma is world class! 💊✨
M
Michael C
Interesting to see how companies will balance their product mix. This could actually push Indian pharma to innovate more rather than just compete on price. Every challenge brings opportunity!
K
Kavya N
Our government should focus on boosting domestic API production too. Too much dependence on China for raw materials makes us vulnerable in these trade wars. Make in India should mean REAL Make in India.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50